Advertisement

 

 

Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity.

Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity.
Author Information (click to view)

Giesler KE, Marengo J, Liotta DC,


Giesler KE, Marengo J, Liotta DC, (click to view)

Giesler KE, Marengo J, Liotta DC,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Journal of medicinal chemistry 2016 07 2259(15) 7097-110 doi 10.1021/acs.jmedchem.6b00428

Abstract

The therapeutic value of numerous small molecules hinges on their ability to permeate the plasma membrane. This is particularly true for tenofovir (TFV), adefovir, and other antiviral nucleosides that demonstrate potent antiviral activity but poor bioavailability. Using TFV as a model substrate, we hybridized two disparate prodrug strategies to afford novel reduction-sensitive lipid conjugates of TFV that exhibit subnanomolar activity toward HIV-1 and are stable in human plasma for more than 24 h with a therapeutic index approaching 30000. These compounds significantly rival the clinically approved formulation of TFV and revitalize the potential of disulfide-bearing prodrugs which have seen limited in vitro and in vivo success since their debut over 20 years ago. We further demonstrate the utility of these conjugates as a tool to indirectly probe the enzymatic hydrolysis of phosphonomonoesters that may further advance the development of other prodrug strategies for nucleosides, peptides, and beyond.

Submit a Comment

Your email address will not be published. Required fields are marked *

4 × five =

[ HIDE/SHOW ]